A Humble Bacterium Sweeps This Year's Nobel Prize  by Mégraud, Francis
Leading Edge
EssayA Humble Bacterium Sweeps  
This Year’s Nobel Prize
Francis Mégraud1,*
1INSERM ERI-10, Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, Bordeaux, France
*Contact: francis.megraud@chu-bordeaux.fr
DOI: 10.1016/j.cell.2005.11.032
Earlier this month, the Nobel Prize in Physiology or Medicine was awarded to the Austra-
lians Barry Marshall and Robin Warren for their discovery of the bacterium Helicobacter 
pylori and its role in peptic ulcer disease and gastric cancer. It is the first time since 1928 
that the Nobel Prize has been awarded for the discovery of a bacterium, and H. pylori is the 
first bacterium to be associated with cancer.It was Robin Warren, a pathologist 
working in Perth, who, 25 years ago, 
first noted that spiral bacteria colonized 
the lower part of the stomach (antrum) 
in about half of the patients from which 
he had taken biopsies. Crucially, he 
noted that inflammation of the mucosal 
lining of the stomach (gastritis) always 
appeared close to the location of the 
spiral bacteria. Intrigued by these find-
ings, Barry Marshall, a young clinical 
fellow, teamed up with Warren (see 
Figure 1), and together they assayed 
stomach biopsies from 100 patients.
Researchers working on Helico-
bacter look back on the date of Easter 
1982 as the “birthday” of H. pylori. This 
is the date that Marshall was first able 
to culture H. pylori from biopsy material 
in the laboratory. Thinking that H. pylori 
was related to another gram-negative 
bacterium called Campylobacter, Mar-
shall decided to try growing H. pylori 
on agar plates usually used for cul-
turing Campylobacter. Although such 
plates are normally discarded after 2 or 
3 days, there was the fortuitous inter-
vention of the Easter holiday. Arriving 
back from a 4-day break, Marshall dis-
covered colonies of H. pylori thanks to 
the extended incubation period (War-
ren and Marshall, 1983).
There followed a frenzy of research 
that began to unravel the mysteries 
of H. pylori, with data appearing on 
the characteristics of the bacterium, 
methods to diagnose it, and the host 
immune response (Marshall and War-
ren, 1984). Marshall and Warren went 
on to show that H. pylori is found in almost all individuals with gastritis, 
peptic ulcers, and duodenal ulcers. 
Indeed, more than 80% of stomach 
ulcers and 90% of duodenal ulcers 
are known to be caused by H. pylori. 
Furthermore, it became clear that 
stomach cancer can result in infected 
individuals where H. pylori causes 
widespread inflammation of the stom-
ach lining (IARC Working Group, 
1994). Inflammation is also associ-
ated with a rare stomach tumor called 
MALT (mucosa-associated lymphoid 
tissue) lymphoma. About 50% of indi-
viduals worldwide are infected with H. 
pylori (usually passed from mother to 
child) and develop gastritis, but many 
remain asymptomatic. Peptic ulcer 
disease arises in 10% of infected peo-
ple, gastric adenocarcinoma in 1%, 
and gastric MALT lymphoma in less 
than 0.1%.
Figure 1. Barry Marshall and Robin 
Warren with the Author
Barry Marshall (left) and Robin Warren (center) 
with the author (right), who presented the award 
of the European Helicobacter pylori Study 
Group to Marshall and Warren at their Lisbon 
meeting in 1997. Cell 123, DeceConvincing the Skeptics
The implication that an infectious agent 
could be the cause of peptic ulcer dis-
ease was a revolutionary idea in the 
1980s, and one that was greeted with 
skepticism by the medical community. 
At that time, there were numerous the-
ories to explain the etiology of peptic 
and duodenal ulcers, including the link-
ing of ulcers to lifestyle and stress. The 
most popular theory was that ulcers 
developed in response to excess acid 
in the stomach. This resulted in the 
development of drugs that blocked 
H2 receptors expressed by stomach 
parietal cells, which when activated, 
induced the cells to produce acid. It 
is ironic that Sir James W. Black was 
awarded the 1988 Nobel Prize in Phys-
iology or Medicine for discovering H2 
receptors. His work paved the way for 
the development of H2 receptor-block-
ing drugs to treat peptic ulcer disease. 
Such drugs changed the management 
of this disease because gastric sur-
gery became limited to cases of stom-
ach perforation or gastric malignancy. 
However, the H2 receptor-blocking 
drugs and their successors, the pro-
ton-pump inhibitors, only treated the 
symptoms of peptic ulcer disease, and 
the frequent relapses necessitated 
lifelong maintenance treatment.
The first time that Marshall and War-
ren presented their work at a national 
meeting in Australia, it was rejected 
outright. Whereas Warren was too 
shy to push their remarkable findings, 
Marshall had a missionary’s zeal and 
vigorously defended their research. In mber 16, 2005 ©2005 Elsevier Inc. 975
order to convince the reluctant medical 
community of the robustness of their 
discovery, Marshall did the ultimate 
experiment. He drank a culture of H. 
pylori, developed acute gastritis and 
then successfully treated the illness 
with antibiotics (Marshall et al., 1985). 
Thanks to the discovery of Marshall 
and Warren and Marshall’s definitive 
experiment, a lifelong treatment was 
suddenly replaced by a short course 
of antibiotics (NIH Consensus Confer-
ence, 1994). In addition, MALT lym-
phoma could be successfully treated 
by eradicating H. pylori infection, mak-
ing it the first human cancer to be cured 
by antibiotics. These developments did 
not please the pharmaceutical indus-
try, although it was still necessary to 
prescribe antisecretory drugs in order 
to increase the stomach’s pH, thus 
allowing the antibiotics to do their job.
H. pylori: Opening up New 
Avenues of Research
Among the more than 20,000 articles 
about H. pylori published since 1983, 
many have been devoted to the study 
of the bacterium and understanding 
its secrets. We now know that Helico-
bacter is very heterogeneous. Not only 
mammals but many other vertebrates 
carry their own specific Helicobacter 
species, most of which are harmless 
commensals. In contrast, H. pylori 
induces inflammation in its human host 
and cannot be considered a commen-
sal. In 1997, H. pylori became the third 
bacterium to have its genome totally 
sequenced (Tomb et al. 1997), and in 
1999, it became the first bacterium for 
which the genome sequences for two 
strains were obtained. The discovery of 
the so-called cag pathogenicity island 
in H. pylori reveals how commensal 
bacteria acquire beneficial proper-
ties that give them the upper hand in 
the bacteria-host relationship. Genes 
contained within the cag pathogenic-
ity island encode proteins that enable 
H. pylori to transfer molecules to the 
cytosol of host gastric epithelial cells 
and to interfere with host cell signaling 
pathways. Recently, the CagA protein 
has been shown to disrupt the organi-
zation and assembly of apical junctions 
in epithelial cells and also to perturb 
epithelial cell differentiation (Bagnoli 976 Cell 123, December 16, 2005 ©2005 Eet al., 2005; see Cell Biology Select, 
page 963 of this issue). In addition, 
molecules comprising the H. pylori cell 
wall, especially muramyl dipeptides, 
are recognized by host epithelial cell 
NOD receptors leading to activation of 
the NF-κB signaling pathway and pro-
duction of interleukin 8, a proinflam-
matory cytokine (Viala et al., 2004).
Within the last 5 years, it has become 
clear that host factors are involved in 
the pathogenesis of H. pylori. Gastric 
carcinoma has been linked to a poly-
morphism in the interleukin-1β (IL-1β) 
gene. Certain IL-1β/IL-1β receptor gen-
otypes are associated with atrophy of 
the gastric mucosa due to the ability of 
this cytokine to block acid production. 
Indeed, when IL-1β is produced in large 
amounts, the risk of gastric carcinoma 
increases (El Omar et al., 2000).
Another important discovery reveals 
that the gastric mucosa cells that 
become tumorigenic are mesenchy-
mal stem cells originating in the bone 
marrow. An elegant study using mice 
repopulated by stem cells harboring 
different markers showed that in ani-
mals with a long-term Helicobacter 
felis infection, stem cells homed to 
gastric tissue and, because of the 
inflammatory environment, became 
tumorigenic (Houghton et al., 2004). 
We await confirmation of this intrigu-
ing finding in other carcinomas where 
inflammation is present.
There are other domains beyond 
pathogenicity where the discovery of H. 
pylori has opened up new avenues of 
research. One such example is phylo-
geography, given that H. pylori has been 
associated with humans for thousands 
of years. By comparing sequences of 
housekeeping genes of H. pylori from 
human populations in different geo-
graphical areas, it is possible to identify 
strain genotypes. Models can then be 
developed to infer the ancient geno-
types of this bacterium. Such studies 
reveal ancient human migrations, such 
as the migration of Amerindians from 
Asia, the Maori from Southeast Asian 
islands, and the Bantu from Cen-
tral Africa (Falush et al., 2003). Such 
microbial studies complement data on 
ancient human migrations derived from 
genetics, mitochondrial DNA analyses, 
and language studies.lsevier Inc.Marshall and Warren’s seminal dis-
covery that a humble bacterium, H. 
pylori, causes gastritis, peptic and 
duodenal ulcers, and in some cases, 
gastric cancer, merits the 2005 Nobel 
Prize in Physiology or Medicine for its 
remarkable impact on public health 
and for opening up new avenues 
of research. This low-tech discov-
ery in the final decades of the 20th 
century—which saw the explosion 
of technology and the emphasis on 
mechanistic approaches to research—
demonstrates that not all discoveries 
require a high-tech laboratory and the 
latest equipment. The tenacity of Mar-
shall and Warren illustrates that impor-
tant discoveries can still be made by 
doggedly pursuing unexpected results 
with an open mind.
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